FDA announces Class III recall for Ziac blood pressure tablets

Over 11,000 bottles of a high blood pressure medication have been recalled for potential cross contamination with another drug.

Glenmark Pharmaceuticals Inc., based in New Jersey, has voluntarily recalled thousands of units of bisoprolol fumarate and hydrochlorothiazide tablets (Ziac) for potentially containing amounts of a high cholesterol drug, according to NewsNation.

The drugmaker tested reserve samples, which revealed the presence of ezetimibe, a drug used to treat high cholesterol.

The Federal Drug Administration classified the recall with a Class III risk level. This means the use or exposure to the recalled product “is not likely to cause adverse health consequences,” according to the FDA.

Affected tablets range from 2.5 mg to 6.25 mg dosages in different bottle sizes with expiration dates starting November 2025 through December 2026.

Consumers can identify affected lots by these lot codes:

30-count bottles, NDC-68462-878-30100-count bottle, NDC-68462-878-01500-count bottle, NDC-68462-878-05

Glenmark and the FDA have yet to issue recommendations on what to do with the recalled drug.